Ziconotide
Also known as Prialt, SNX-111
A synthetic cone snail venom peptide for severe chronic pain. The first intrathecal non-opioid analgesic FDA approved.
Regulatory Pathway
Dosing Protocol
Typical Dose
Via intrathecal pump (individualized)
Frequency
Continuous intrathecal infusion
Duration
Chronic use via intrathecal pump
Timing & Administration
Administer via Intrathecal infusion only. Frequency: Continuous intrathecal infusion.
Popular Uses
Mechanism of Action
Blocks N-type voltage-gated calcium channels (Cav2.2) in the spinal cord. Prevents neurotransmitter release from pain-signaling neurons, providing analgesia without opioid receptor involvement.
Research Summary
Evidence level: fda approved. Clinical status: FDA Approved - Severe chronic pain.
Side Effects & Safety
Important Warnings
- BLACK BOX WARNING: Severe psychiatric symptoms
References
No references available.
Related Peptides
Browse all →A synthetic peptide derived from a protein found in human gastric juice. Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract.
View profileA synthetic 17-amino acid fragment of Thymosin Beta-4 with a longer half-life (~2-4 days) compared to the full protein (~2 hours).
View profileA GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
View profile